Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

After hours: January 29 at 6:13:01 PM EST Loading Chart for BLCO ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

City Therapeutics will develop an RNAi clinical candidate for intravitreal administration targeting retinal diseases, including geographic atrophy. Bausch + Lomb will manage IND-enabling studies, ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial ...

It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...

VAUGHAN, Ontario, January 22, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its ...

Bausch + Lomb in December confirmed that a sale was “one of several options being explored to complete a full separation from Bausch Health Companies Inc.,” making the statement in response to ...